Journal Club E60: Suzetrigine: A New Class of Pain Relief, Minus the Hype

from AZense Journal Club · host Azense Medical Education

Suzetrigine (Journavx) is the first genuinely new pharmacologic class of pain medicine since the COX-2 inhibitors. It beat placebo and carries no addiction liability, but it did not outperform a generic opioid on pain, and its chronic-pain data remain unproven.

Episode metadata supplied by the publisher feed · Published May 25, 2026

Embed this episode

Attribution link and audio player

Ready to play

Journal Club E60: Suzetrigine: A New Class of Pain Relief, Minus the Hype

0:00 6:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of AZense Journal Club?

This episode is 6 minutes long.

When was this AZense Journal Club episode published?

This episode was published on May 25, 2026.

Can I download this AZense Journal Club episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!